Cited by

• Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.

  Lee YC, Dong YH, Yang WS, Wu LC, Lin JW, Chang CH. Lee YC, et al. Front Pharmacol. 2022 Sep 13;13:869804. doi: 10.3389/fphar.2022.869804. eCollection 2022. Front Pharmacol. 2022. PMID: 36176438 Free PMC article.
• Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

  Milder TY, Stocker SL, Day RO, Greenfield JR. Milder TY, et al. Drug Saf. 2020 Dec;43(12):1211-1221. doi: 10.1007/s40264-020-01010-6. Epub 2020 Oct 23. Drug Saf. 2020. PMID: 33095409 Free PMC article. Review.
• Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

  Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Verma S, et al. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19. Diabetologia. 2018. PMID: 29777264 Free PMC article. Clinical Trial.
• The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.

  Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y, Pomerantz A, Ben-Zvi I, Dankner R, Maor E. Goldman A, et al. Cardiovasc Diabetol. 2023 Jan 24;22(1):16. doi: 10.1186/s12933-023-01743-5. Cardiovasc Diabetol. 2023. PMID: 36694178 Free PMC article.
• Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

  Scheen AJ. Scheen AJ. Nat Rev Endocrinol. 2020 Oct;16(10):556-577. doi: 10.1038/s41574-020-0392-2. Epub 2020 Aug 27. Nat Rev Endocrinol. 2020. PMID: 32855502 Review.